Urine proteomics profiling of the COVID-19
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Homo Sapiens (ncbitaxon:9606)
SUBMITTER: 
Ping Xu
PROVIDER: MSV000085516 | MassIVE | Sat May 30 12:44:00 BST 2020
SECONDARY ACCESSION(S): PXD018970
REPOSITORIES: MassIVE
Similar Datasets
Project description:Targeted mass spectrometric assays for the 22 proteins in a second test cohort containing 19 COVID-19 patients<ul><li>Dataset imported into MassIVE from <a href="https://www.iprox.org/page/project.html?id=IPX0002171000">https://www.iprox.org/page/project.html?id=IPX0002171000</a> on 05/30/20</li></ul>
2020-05-30 | MSV000085515 | MassIVE
Project description:Targeted mass spectrometric assays for the 22 proteins in a second test cohort containing 19 COVID-19 patients<ul><li>Dataset imported into MassIVE from <a href="https://www.iprox.org/page/project.html?id=IPX0002171000">https://www.iprox.org/page/project.html?id=IPX0002171000</a> on 05/30/20</li></ul>
2020-05-30 | MSV000085515 | GNPS
Project description:Early detection and effective treatment of severe COVID-19 patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model was validated using ten independent patients, seven of which were correctly classified. Targeted proteomics and metabolomics assays were employed to further validate this molecular classifier in a second test cohort of 19 new COVID-19 patients, leading to 16 correct assignments. We identified molecular changes in the sera of COVID-19 patients compared to other groups implicating dysregulation of macrophage, platelet degranulation and complement system pathways, and massive metabolic suppression. This study revealed characteristic protein and metabolite changes in the sera of severe COVID-19 patients, which might be used in selection of potential blood biomarkers for severity evaluation.<ul><li>Dataset imported into MassIVE from <a href="https://www.iprox.org/page/project.html?id=IPX0002106000">https://www.iprox.org/page/project.html?id=IPX0002106000</a> on 05/29/20</li></ul>
2020-05-29 | MSV000085507 | MassIVE
Project description:A Comparative Study of Human Testes and Epididymis through the Proteomics and RNA-seq Methods
<ul><li>Dataset imported into MassIVE from <a href="https://www.iprox.cn/page/project.html?id=IPX0003098000">https://www.iprox.cn/page/project.html?id=IPX0003098000</a> on 12/10/21</li></ul>
2021-12-13 | MSV000088554 | MassIVE
Project description:Early detection and effective treatment of severe COVID-19 patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model was validated using ten independent patients, seven of which were correctly classified. Targeted proteomics and metabolomics assays were employed to further validate this molecular classifier in a second test cohort of 19 new COVID-19 patients, leading to 16 correct assignments. We identified molecular changes in the sera of COVID-19 patients compared to other groups implicating dysregulation of macrophage, platelet degranulation and complement system pathways, and massive metabolic suppression. This study revealed characteristic protein and metabolite changes in the sera of severe COVID-19 patients, which might be used in selection of potential blood biomarkers for severity evaluation.<ul><li>Dataset imported into MassIVE from <a href="https://www.iprox.org/page/project.html?id=IPX0002106000">https://www.iprox.org/page/project.html?id=IPX0002106000</a> on 05/29/20</li></ul>
2020-05-29 | MSV000085507 | GNPS
Project description:<p>The objective of the Time-Dependent Proteome Study, was to evaluate changes in the proteome and phosphoproteome when there is a delay in freezing tissues following sample (tumor) excision. The biospecimens used are from patient-derived ovarian cancer tumors.<br><a href="http://www.ncbi.nlm.nih.gov/pubmed/24719451" target="_blank">Ref: Mertins P et al., (2014) Mol Cell Proteomics, Apr 9. E-Publication</a><br><a href="http://www.ncbi.nlm.nih.gov/pubmed/25670172" target="_blank">Ref: Gajadhar, A.S., et al., (2015) Cancer Res. Apr 1;75(7):1495-503. Epub 2015 Feb 10.</a></p><ul><li>Dataset imported into MassIVE from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S013">https://cptac-data-portal.georgetown.edu/cptac/s/S013</a> on 11/05/18</li></ul>
2018-11-05 | MSV000083107 | MassIVE
Project description:<p>The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing. TCGA is a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), which are both part of the National Institutes of Health, U.S. Department of Health and Human Services.</p> <p>TCGA projects are organized by cancer type or subtype. Click <a href="http://cancergenome.nih.gov/cancersselected" target="_blank">here</a> for a current list of cancer types selected for study in TCGA.</p> <p>Data from TCGA (e.g., gene expression, copy number variation and clinical information), are available via the <a href="https://tcga-data.nci.nih.gov/tcga/" target="_blank">TCGA Data Portal</a>, EXCEPT for the genomic sequence data (.bam files), which are hosted at the <a href="https://cghub.ucsc.edu/" target="_blank">Cancer Genomics Hub (CGHub)</a>.</p> <p>Data from TCGA projects are organized into two tiers: <b>Open Access and Controlled Access</b>. <ul> <li>Open Access data tier contains data that cannot be attributed to an individual research participant. The Open Access data tier does not require user certification. Data in Open Access tier are available in the TCGA Data Portal.</li> <li>Controlled Access data tier contains individual-level genotype data that are unique to an individual. Access to data in the Controlled Access data tier requires user certification through <a href="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?login=&page=login" target="_blank">dbGaP Authorized Access</a>.</li> <li>Controlled Access data types consist of the following: <ul> <li>Individual germline variant data (SNP .cel files)</li> <li>Primary sequence data (.bam files), which are available at CGHub</li> <li>Clinical free text fields</li> <li>Exon Array files (for Glioblastoma and Ovarian projects only)</li> </ul> </li> </ul> </p> <p><b>NOTE: TCGA strives to release most data in the open access tier. Individual genotype or sequence files are prominent exceptions. Commonly requested files such as descriptions of somatic mutations or clinical data are open access.</b></p> <p><b>The TCGA study is utilized in the following dbGaP substudies.</b> To view genotypes and other molecular data collected in these substudies, please click on the following substudies below or in the "Substudies" box located on the right hand side of this top-level study page phs000178 TCGA study. <ul> <li><a href="./study.cgi?study_id=phs000441">phs000441</a> Integrated Genomic Analyses of Ovarian Carcinoma (OV)</li> <li><a href="./study.cgi?study_id=phs000489">phs000489</a> Comprehensive Genomic Characterization Defines Human Glioblastoma Genes and Core Pathways</li> </ul> </p>
| phs000178.v6.p6 | EGA
Project description:The objective of the "System Suitability (CompRef) Study" was to validate mass spectrometry protocols used at each Proteome Characterization Center (PCC).
<ul><li>Dataset imported into MassIVE from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S010">https://cptac-data-portal.georgetown.edu/cptac/s/S010</a> on 10/22/19</li></ul>
2019-10-23 | MSV000084497 | MassIVE
Project description:The objective of the Time-Dependent Proteome Study was to evaluate changes in the proteome and phosphoproteome when there is a delay in freezing tissues following sample (tumor) excision. The biospecimens used are from human-in-mouse breast cancer tumor samples.<br/><a href="http://www.ncbi.nlm.nih.gov/pubmed/24719451" target="_blank">Ref: Mertins P et al., (2014) Mol Cell Proteomics, Apr 9. E-Publication</a><ul><li>Dataset imported into MassIVE from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S011">https://cptac-data-portal.georgetown.edu/cptac/s/S011</a> and <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S012">https://cptac-data-portal.georgetown.edu/cptac/s/S012</a> on 08/29/19</li></ul>
2019-08-30 | MSV000084260 | MassIVE
Project description:<p>The objective of the Time-Dependent Proteome Study was to evaluate changes in the proteome and phosphoproteome when there is a delay in freezing tissues following sample (tumor) excision. The biospecimens used are from snap-frozen colon adenocarcinoma core biopsy punches.<br/><a href="http://www.ncbi.nlm.nih.gov/pubmed/25670172" target="_blank">Ref: Gajadhar, A.S., et al., (2015) Cancer Res. Apr 1;75(7):1495-503. Epub 2015 Feb 10.</a></p><ul><li>Dataset imported into MassIVE from <a href="https://cptac-data-portal.georgetown.edu/cptac/s/S023">https://cptac-data-portal.georgetown.edu/cptac/s/S023</a> on 08/28/19</li></ul>
2019-08-28 | MSV000084243 | MassIVE